Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Mazdutide (IBI362) in Chinese Participants With Obesity or Overweight
NCT05607680Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in obesity, Overweight, sponsored by Innovent Biologics. Started Nov 2022; status: completed.
02
Drugs
mazdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05607680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607680.